000			02050na a2200229 4500
003			H12O
005			20180417112636.0
008			130622s2012 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aCastro Panete, María José _92010 _eInmunología
245	0	0	_aProspective Study of Biomarkers of Immune Response in Lung Transplant Recipients. _h[artículo]
260			_bTransplantation Proceedings, _c2012
300			_a44(9):2666-8.
500			_aFormato Vancouver: San Segundo D, Brunet M, Ballesteros MA, Millán O, Muro M, Castro MJ, et al. Prospective study of biomarkers of immune response in lung transplant recipients. Transplant Proc. 2012 Nov;44(9):2666-8.
501			_aPMID: 23146488
504			_aContiene 10 referencias
520			_aStudies on biomarkers of tolerance in organ transplantation have been widely performed during the last decade. Aim. To assess biomarkers in relation to evolution of the immune response among lung transplant recipients. Methods. This multicenter study included 27 lung transplant recipients followed before as well as at 7, 14, 30, 60, 90, and 180 days posttransplantation. Biomarkers of the immune response based on flow cytometry technology were validated in each center. They included intracellular cytokine expression, regulatory T-cell level, as well as lymphocyte surface antigen and CD28 expressions. Results. The 13 patients who developed acute rejection episodes showed increased numbers of regulatory T cells at 12 months posttransplant. Sixteen patients experiencing infections displayed decreased expression of CD69 on CD8 T cells within the first year of follow-up. Conclusion. High Treg levels in the peripheral blood of lung transplant recipients were associated with an increased risk of rejection but not infection. Inversely, we observed low levels of activated CD8 T cells in infected patients.
710			_9395 _aServicio de Inmunología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/8/pc8381.pdf _ySolicitar documento
942			_n0 _2ddc _cART
999			_c8381 _d8381